Pfizer China: Major Structural Adjustment Again

Author: Joanna

On August 11, 2025, Pfizer China announced an organizational restructuring of its Oncology and Rare Disease Business Unit, aimed at strengthening strategic focus, enhancing operational efficiency, accelerating business development in key therapeutic areas, and laying the foundation for the launch of major innovative products. The new structure will take effect officially from August 11, 2025, with adjustments in the lung cancer treatment area to be implemented starting September 1.

On March 17, 2025, Pfizer China announced a significant leadership and organizational restructuring aimed at further driving the company's growth and innovation in the Chinese market, and announced that Li Jinhui will assume the role of General Manager of the Oncology and Rare Disease Business Unit.

It is understood that this adjustment by the Oncology and Rare Diseases Division comes after the management team, since Li Jinhui took office as General Manager of the division in March this year, conducted in-depth frontline research and business reviews, comprehensively assessed the current team status and market opportunities, and finalized the adjustment plan following thorough discussions.

Under the new structure, the blood disorders and rare diseases therapy areas will be divided into two key business units:

BG&H Franchise is managed by Wang Chi, integrating hematology-oncology and breast/uro-oncology businesses, with a focus on related therapeutic areas;

RD Franchise is led by Gu Guangping, integrating the hemophilia and ATTR teams, focusing on rare disease treatments and accelerating the introduction and localization of innovative products.

Wang Jihua will continue to lead the lung cancer treatment field, with operations focusing on optimizing regional deployment and resource allocation across the three major regions—North China, South China, and East China—to drive sustained growth in this sector.

In terms of market, the Boryana market team is led by Chen Jieying, and the Zegemia market team is led by Zhang Ying. The two teams will cover different regions, strengthening product promotion and brand influence.

Wang Chi (chí):

Graduated from China Pharmaceutical University in 2002 with a bachelor's degree in microbiology.

Main professional experience (in chronological order)

1. Shire, Otsuka Pharmaceutical of Japan

Initially worked for Schering-Plough and Otsuka Pharmaceutical of Japan after graduation, launching a career in the pharmaceutical industry.

2. Merck China (approximately 2010–2021)

- Worked at Merck for approximately 12 years, holding positions including Regional Promotion Manager, Senior Area Manager, Regional Manager, and Regional Sales Director, eventually serving as Sales Director for the Oncology Business Unit;

- Responsible for nationwide sales and regional marketing management of oncology and anti-infective product lines, including Keytruda, and received multiple company awards and the General Manager's Special Contribution Award.

3. Pfizer China (2022–present)

January 27, 2022

- Appointed as Head of the Breast Cancer Therapeutic Area in the Oncology Business Unit, overseeing the sales and marketing teams for the breast cancer product portfolio.

2023–2024

- Expanded role to "Head of Breast Cancer and Urologic Tumor Therapeutics," reporting directly to the General Manager of the Oncology Business Unit.

Starting from August 11, 2025

- Pfizer China's Oncology and Rare Disease Business Unit has undergone a structural adjustment, with Wang Chi appointed as the BG&H Franchise Lead, fully integrating hematology oncology, breast oncology, and urology oncology operations, further strengthening its focus on treatments for blood cancers and breast/urologic cancers.

Ko Kohei:

Graduated from Sichuan University with a bachelor's degree, he is an industry role model who rose from a medical representative to a senior executive at Pfizer.

Professional Experience (Chronological Order)

1. 2007 – Present: Pfizer China

Joined Pfizer in 2007 as a sales representative and was subsequently promoted through the following positions:

• Regional/Sales Manager

• Director of Market Expansion Strategy and Access for Anti-Infective Product Line

• North China Sales Director, Anti-infective Business

Responsible for the entire anti-infective product business in over 20 provinces and municipalities, including Beijing, Tianjin, Hebei, Shanxi, Inner Mongolia, the three northeastern provinces, Sichuan-Chongqing, Yunnan-Guizhou, and Shaanxi-Gansu-Ningxia-Qinghai-Tibet-Xinjiang.

2. September 2023 – Present: Head of Northern Region Sales Team for Innovative Products, Emergency Care Division, Hospital Department

• Following Pfizer China's restructuring of its Hospital Acute Care business unit into two divisions—"Core Products Business Line" and "Innovative Products Business Line"—Gu Guangping was appointed head of the Innovative Products North China sales team, responsible for leading sales and team management of innovative products such as Zavicefta, Zavicefta/Zevtera, and Paxlovid in North China.

Wang Jihua:

2007 to present: Joined Pfizer, serving in various positions including Sales Representative, Regional Manager, Area Manager, and National Sales Director.

• Starting September 1, 2023: Pfizer China Hospital Acute Care business underwent organizational restructuring, with Ji-Hua Wang appointed as head of the Innovative Products Marketing Team, fully responsible for brand strategy, marketing, and team management of innovative products such as Zavicefta, Zavicefta, and Paxlovid in the Chinese market.